Disc Medicine Positive Trial Results Prompt BMO Capital to Reaffirm IRON Outperform Rating

Key Facts

1Disc Medicine announced positive Phase 2 clinical trial results for DISC-3405 and selcodebart in treating hematologic disorders.

2BMO Capital reaffirmed its 'Outperform' rating for IRON stock following data presentation at the SOHO annual meeting.

In a move reflecting the ongoing innovation within the biotechnology sector, Disc Medicine announced positive initial results from its RESTORE-PV Phase 2 trial for DISC-3405, a treatment for polycythemia vera. According to reports, the drug demonstrated efficacy in reducing the need for phlebotomy in patients, while the company also presented promising data for selcodebart in treating anemia associated with myelofibrosis during the SOHO annual meeting.

Following these clinical developments, BMO Capital reaffirmed its "Outperform" rating for IRON stock, suggesting expectations that the equity will exceed broader market performance. These advancements come as the company ramps up engagement with the financial community through several investor conferences, leveraging the success of DISC-3405 as the first monoclonal antibody targeting the TMPRSS6 protein.

Per market data, IRON was priced at $76.51 at the close of September 9, 2026, within a daily trading range of $75.24 to $77.27. Investors are now watching for further catalysts from upcoming investor presentations, following recent US economic data such as the ISM Services PMI, which reported a reading of 55.4 earlier this month.